Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy



      Current recommendations regarding radiotherapy treatment for unfavorable intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT) ± brachytherapy boost (BT) ± androgen deprivation therapy (ADT). The ideal radiotherapy treatment approach for UIR-PCa has not been well-defined. We hypothesized that EBRT+BT±ADT is associated with improved overall survival (OS) relative to EBRT±ADT in men with UIR-PCa.


      The National Cancer Database (NCDB) was used to retrospectively identify 32,246 men diagnosed between 2004 and 2015 with UIR-PCa who received EBRT (n = 13,265), EBRT+ADT (n = 13,123), EBRT+BT (n = 3440), or EBRT+BT+ADT (n = 2418). OS was the primary outcome. Inverse probability of treatment weighting was used to adjust for covariable imbalances and weight-adjusted multivariable analysis using Cox regression modeling was used to compare OS hazard ratios.


      Median follow-up was 60 months (range: 3–168 months). EBRT+ADT correlated with improved OS relative to EBRT alone on multivariable analysis (Hazard Ratio (HR): 0.92, [95% Confidence Interval: 0.87–0.98], p = 0.005). Compared to EBRT+ADT, EBRT+BT (HR: 0.77 [0.69–0.85], p = 3 × 10−7) and EBRT+BT+ADT (HR: 0.75 [0.67–0.83], p = 6 × 10−8) were associated with improved OS. Eight-years OS for the EBRT+ADT versus EBRT+BT+ADT was 70% and 78% (p < 0.0001), which is similar to historical clinical trials (ASCENDE-RT 9-year OS: 74% vs. 78%, p = 0.29). Relative to EBRT+BT, EBRT+BT+ADT was not associated with improved OS (HR: 0.99 [0.87–1.11], p = 0.82).


      In a large retrospective cohort, the addition of brachytherapy to EBRT correlated with improved survival in men with UIR-PCa. Men receiving EBRT+ADT+BT had improved OS relative to EBRT+ADT. The addition of ADT to EBRT, but not to EBRT+BT, correlated with improved OS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Prostate cancer (version 2.2021). Accessed March 2, 2021.

        • Dinh K.T.
        • Mahal B.A.
        • Ziehr D.R.
        • et al.
        Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer.
        J Urol. 2015; 194: 343-349
        • Dearnaley D.P.
        • Jovic G.
        • Syndikus I.
        • et al.
        Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial.
        Lancet Oncol. 2014; 15: 464-473
        • Michalski J.M.
        • Moughan J.
        • Purdy J.
        • et al.
        Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial.
        JAMA Oncol. 2018; 4e180039
        • Zietman A.L.
        • Bae K.
        • Slater J.D.
        • et al.
        Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95-09.
        J Clin Oncol. 2010; 28: 1106-1111
        • D'Amico A.V.
        • Moran B.J.
        • Braccioforte M.H.
        • et al.
        Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.
        J Clin Oncol. 2009; 27: 3923-3928
        • Jones C.U.
        • Hunt D.
        • McGowan D.G.
        • et al.
        Radiotherapy and short-term androgen deprivation for localized prostate cancer.
        N Engl J Med. 2011; 365: 107-118
        • Zumsteg Z.S.
        • Spratt D.E.
        • Daskivich T.J.
        • et al.
        Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: A secondary analysis of the RTOG 9408 randomized clinical trial.
        JAMA Netw Open. 2020; 3e2015083
        • Zumsteg Z.S.
        • Spratt D.E.
        • Pei I.
        • et al.
        A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
        Eur Urol. 2013; 64: 895-902
        • Hoskin P.J.
        • Rojas A.M.
        • Bownes P.J.
        • et al.
        Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
        Radiother Oncol. 2012; 103: 217-222
        • Morris W.J.
        • Tyldesley S.
        • Rodda S.
        • et al.
        Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
        • Sathya J.R.
        • Davis I.R.
        • Julian J.A.
        • et al.
        Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.
        J Clin Oncol. 2005; 23: 1192-1199
        • Cole S.R.
        • Hernan M.A.
        Constructing inverse probability weights for marginal structural models.
        Am J Epidemiol. 2008; 168: 656-664
        • Austin P.C.
        • Stuart E.A.
        Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.
        Stat Med. 2015; 34: 3661-3679
        • Johnson S.B.
        • Lester-Coll N.H.
        • Kelly J.R.
        • et al.
        Brachytherapy boost utilization and survival in unfavorable-risk prostate cancer.
        Eur Urol. 2017; 72: 738-744
        • Kishan A.U.
        • Cook R.R.
        • Ciezki J.P.
        • et al.
        Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer.
        JAMA. 2018; 319: 896-905
        • Joseph D.
        • Denham J.W.
        • Steigler A.
        • et al.
        Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial.
        Int J Radiat Oncol Biol Phys. 2020; 106: 693-702
        • Davis B.J.
        • Pisansky T.M.
        • Wilson T.M.
        • et al.
        The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy.
        Cancer. 1999; 85: 2630-2637
        • Sohayda C.
        • Kupelian P.A.
        • Levin H.S.
        • et al.
        Extent of extracapsular extension in localized prostate cancer.
        Urology. 2000; 55: 382-386
        • Jackson W.C.
        • Hartman H.E.
        • Dess R.T.
        • et al.
        Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: A network meta-analysis of randomized trials.
        J Clin Oncol. 2020; 38: 3024-3031
        • Dattoli M.
        • Wallner K.
        • True L.
        • et al.
        Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy.
        J Oncol. 2010; 2010
        • Demanes D.J.
        • Brandt D.
        • Schour L.
        • et al.
        Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
        Am J Clin Oncol. 2009; 32: 342-347
        • D'Amico A.V.
        • Chen M.H.
        • Renshaw A.A.
        • et al.
        Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial.
        JAMA. 2008; 299: 289-295
        • Nguyen P.L.
        • Alibhai S.M.
        • Basaria S.
        • et al.
        Adverse effects of androgen deprivation therapy and strategies to mitigate them.
        Eur Urol. 2015; 67: 825-836
        • Dobbins T.A.
        • Badgery-Parker T.
        • Currow D.C.
        • et al.
        Assessing measures of comorbidity and functional status for risk adjustment to compare hospital performance for colorectal cancer surgery: A retrospective data-linkage study.
        BMC Med Inform Decis Mak. 2015; 15: 55